Development and Efficacy of Enzyme-Responsive Squalene-Chidamide Nanoparticles for Pancreatic Cancer
Journal of Visualized Experiments · 2026
DOI: 10.3791/69875 ↗At a glance
Video/Audio in Journal of Visualized Experiments, 2026. Written by Kangyu Zhou and 7 co-authors. Institution: School of Pharmaceutical Sciences, Zhejiang Chinese Medical University. Major MEDLINE topics: Nanoparticles, Benzamides, Pancreatic Neoplasms, Squalene. 31 references.
Abstract (original language)
Here, we present a protocol to address the limited intratumoral penetration of small-molecule drugs caused by the dense extracellular matrix (ECM) of pancreatic ductal adenocarcinoma (PDAC). Prodrugs offer great potential to overcome this challenge by enhancing drug penetration and tumor-killing efficacy. Squalene (SQ), a natural precursor for cholesterol biosynthesis with excellent biosafety and biocompatibility, can improve the membrane compatibility of hydrophilic drugs and enhance their cellular uptake when conjugated to chemotherapeutic agents or bioactive small molecules. In this study, we developed a novel lipophilic SQ-based prodrug system: the hydrophilic anticancer drug chidamide (CHI) was conjugated to SQ via an amide bond -- a linkage responsive to pancreatin and cathepsin B (key enzymes overexpressed in the PDAC microenvironment). This conjugation yielded an amphiphilic SQ-CHI prodrug, which was further self-assembled into folate (FA)-modified nanoparticles (FA-SQ-CHI NPs). The optimized NPs exhibited a uniform hydrodynamic diameter of 173.3 ± 1.5 nm, a polydispersity index (PDI) of 0.181 ± 0.18, a high drug loading capacity of 59.0% ± 0.77%, and a stable Zeta potential of -13.10 ± 0.86 mV. In vitro release studies showed that the NPs achieved 80.2% ± 4.22% cumulative drug release within 72 h in the presence of 0.25% pancreatin, while only 33%-38% release was observed in pH-adjusted buffers (pH 4.5 or 7.4) without enzymes. Cellular uptake assays confirmed that FA modification significantly enhanced intracellular delivery efficiency, with 1.8-2.3-fold higher fluorescence intensity in PDAC cells (PSN-1 and CFPAC-1) compared to non-targeted NPs at 12-24 h. The current protocol provides a comprehensive methodology for the synthesis and characterization of the prodrug, in vitro evaluation of enzyme-responsive release kinetics, and comparative analyses of therapeutic efficacy and tissue penetration, highlighting the nanocarrier's core advantages of targeted delivery, high drug loading, and enzyme-triggered controlled release.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University.
- Huzhou Institute for Food and Drug Control.
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University; 202011113511009@zcmu.edu.cn.
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University; Academy of Chinese Medical Sciences, Zhejiang Chinese Medical University; Institute for Innovation in Modern Traditional Chinese Medicine, The Firs…
Cite
APA
Zhou, K., Zhen, H., Wang, W., Luo, J., Wu, F., Li, F., Chen, K., & Gu, M. (2026). Development and Efficacy of Enzyme-Responsive Squalene-Chidamide Nanoparticles for Pancreatic Cancer. Journal of Visualized Experiments. https://doi.org/10.3791/69875
Vancouver
Zhou K, Zhen H, Wang W, Luo J, Wu F, Li F, et al. Development and Efficacy of Enzyme-Responsive Squalene-Chidamide Nanoparticles for Pancreatic Cancer. Journal of Visualized Experiments. 2026. doi:10.3791/69875
BibTeX
@article{Zhou2026,
author = {Zhou, Kangyu and Zhen, Hanyu and Wang, Wenbin and Luo, Jiajia and Wu, Fangping and Li, Fen and Chen, Kaidi and Gu, Mancang},
title = {Development and Efficacy of Enzyme-Responsive Squalene-Chidamide Nanoparticles for Pancreatic Cancer},
journal = {Journal of Visualized Experiments},
year = {2026},
doi = {10.3791/69875}
}
EUVIMED